Lornoxicam

[1]Spyra S, et al. COX-2-selective inhibitors celecoxib and deracoxib modulate transient receptor potential vanilloid 3 channels. Br J Pharmacol. 2017 Aug;174 (16) :2696-2705.|[2]Rose, P. and C. Steinhauser, Comparison of Lornoxicam and Rofecoxib in Patients with Activated Osteoarthritis (COLOR Study) . Clin Drug Investig, 2004. 24 (4) : p. 227-36.|[3]Bianchi, M. and A.E. Panerai, Effects of lornoxicam, piroxicam, and meloxicam in a model of thermal hindpaw hyperalgesia induced by formalin injection in rat tail. Pharmacol Res, 2002. 45 (2) : p. 101-5.|[4]Balfour J A, et al. Lornoxicam: a review of its pharmacology and therapeutic potential in the management of painful and inflammatory conditions[J]. Drugs, 1996, 51: 639-657.|[5]Pohlmeyer-Esch G, et al. Evaluation of chronic oral toxicity and carcinogenic potential of lornoxicam in rats[J]. Food and chemical toxicology, 1997, 35 (9) : 909-922.|[6]Berg J, et al. The analgesic NSAID lornoxicam inhibits cyclooxygenase (COX) -1/-2, inducible nitric oxide synthase (iNOS), and the formation of interleukin (IL) -6 in vitro[J]. Inflammation Research, 1999, 48: 369-379.|[7]Marinov L, et al. The effects of meloxicam, lornoxicam, ketoprofen, and dexketoprofen on human cervical, colorectal, and mammary carcinoma cell lines[J]. Pharmacia, 2024, 71: 1-12.